CNS Drugs (2023) 37:1021–1026
https://doi.org/10.1007/s40263-023-01043-2

ACKNOWLEDGEMENT TO REFEREES

Acknowledgement to Referees

© Springer Nature Switzerland AG 2023

Dear Reader,

Welcome to the final issue of *CNS Drugs* for 2023.

I would like to reflect on this year's achievements and to thank all those who have contributed their valuable time and effort to the journal over the past 12 months.

I would like to start by thanking the authors of the articles published in *CNS Drugs* over the course of 2023. The skill and dedication of these experts is critical to the continued success of the journal.

The high quality of articles published in *CNS Drugs* has been reflected in the most recent Impact Factor of 6.0 and CiteScore of 10.5. These place the journal in the first quartile for Pharmacology and Pharmacy, Clinical Neurology and Psychiatry categories. Further, *CNS Drugs* has published content in a timely manner, with an average time from submission to acceptance of 114 days.

I gratefully acknowledge all of the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

David S. Baldwin, University of Southampton, Southampton, England

Robert L. Barkin, North Shore University Health System and Rush University, Chicago, IL, USA

Thomas R.E. Barnes, Imperial College London, London, England

Michael Berk, Deakin University, Geelong, VIC, Australia

Meir Bialer, The Hebrew University of Jerusalem, Jerusalem, Israel

José Biller, Loyola University Chicago, Maywood, IL, USA

Francesco Brigo, Hospital of Merano (SABES-ASDAA), Merano, Italy

Henry Brodaty, Prince of Wales Hospital, Randwick, NSW, Australia

Martin J. Brodie, West Glasgow Ambulatory Care Hospital, Glasgow, Scotland

Matthew Carpenter, Medical University of South Carolina, Charleston, SC, USA

Marc C. Chamberlain, University of Washington, Seattle, WA, USA

David R. Coghill, Royal Children's Hospital Melbourne, and University of Melbourne, Parkville, VIC, Australia

Samuele Cortese, University of Southampton, Southampton, England

Mervyn J. Eadie, University of Queensland, Brisbane, QLD, Australia

Susanna Every-Palmer, University of Otago, Wellington, New Zealand

Martin R. Farlow, Indiana University School of Medicine, Indianapolis, IN, USA

Giovanni A. Fava, University of Bologna, Bologna, Italy

Susan H. Fox, University Health Network, Toronto, ON, Canada

George T. Grossberg, St Louis University School of Medicine, St. Louis, MO, USA

David Gurwitz, Tel-Aviv University, Tel Aviv, Israel

Martina Hahn, University Hospital Frankfurt, Frankfurt, Germany

Göran Hajak, University of Regensburg, Regensburg, Germany

Hans-Peter Hartung, Heinrich-Heine University, Dusseldorf, Germany

Tomas Kalincik, University of Melbourne, Royal Melbourne Hospital, Melbourne, VIC, Australia

Joshua T. Kantrowitz, Columbia University, New York, NY, USA

David Kemp, Case Western Reserve University, Cleveland, OH, USA

Susan G. Kornstein, Virginia Commonwealth University, Richmond, VA, USA

Patrick Kwan, University of Melbourne, Royal Melbourne Hospital, Melbourne, VIC, Australia

Raymond W. Lam, University of British Columbia, Vancouver, BC, Canada

Simona Lattanzi, Marche Polytechnic University, Ancona, Italy

Lorenzo Leggio, NIAAA and NIDA, NIH, Bethesda, MD, USA

Brian E. Leonard, National University of Ireland, Galway, Ireland

Philip Mitchell, University of New South Wales, Randwick, NSW, Australia

Jeffrey H. Newcorn, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Emilio Perucca, Monash University, Melbourne, VIC, Australia

Robert M. Post, George Washington University, Washington DC and Bipolar Collaborative Network, Washington DC, USA

Alison Poulton, University of Sydney, Nepean Hospital, Penrith, NSW, Australia

Samir K. Praharaj, Kasturba Medical College, Manipal, Karnataka, India

Alan M. Rapoport, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

Olivier Rascol, University Hospital, Toulouse, France

Karen L. Roos, Indiana University Hospital, Indianapolis, IN, USA

Jerrold F. Rosenbaum, Massachusetts General Hospital, Boston, MA, USA

Matthew V. Rudorfer, National Institute of Mental Health, Bethesda, MD, USA

Steven C. Schachter, Beth Israel Deaconess Medical Center, Boston, MA, USA

Soraya Seedat, Stellenbosch University, Cape Town, South Africa

Stephen D. Silberstein, Thomas Jefferson University Hospital, Philadelphia, PA, USA

Per S. Sørensen, Copenhagen University Hospital, Copenhagen, Denmark

Maria Pia Sormani, University of Genoa, Genoa, Italy

David Taylor, Maudsley Hospital, London, England

Claudia Trenkwalder, Paracelsus-Elena Hospital, Kassel, Germany

Eugen Trinka, Paracelsus Medical University Salzburg, Salzburg, Austria

Benedetto Vitiello, University of Turin, Turin, Italy

Bianca Weinstock-Guttman, State University of New York, Buffalo, NY, USA

John W. Winkelman, Harvard Medical School, Boston, MA, USA

Ian C.K. Wong, University of Hong Kong, Hong Kong

John Zajecka, Rush University Medical Center, Chicago, IL, USA

The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would therefore like to thank the following individuals who acted as reviewers for *CNS Drugs* in the last 12 months:

Maurizio Acampa, Italy
Bahman Adlou, USA
Gellan K. Ahmed, Egypt
Martin L. Albert, USA
Patrizia Ambrogini, Italy
Saar Anis, Israel
Elayne Ansara, USA
Chiye J. Aoki, USA
Inmaculada Baeza, Spain
Kathrine B. Madsen, Denmark
Massimo Baraldo, Italy
Alasdair M. Barr, Canada
Francesco Bartoli, Italy
Raman Baweja, USA
Laurel Beckett, USA
Adam A. Behensky, USA
Arnauld Belmer, Australia
Elinor Ben-Menachem, Sweden
Achim Berthele, Germany
Frank M.C. Besag, UK
Miquel Bioque, Spain
Richard K. Bogan, USA
Gauruv Bose, Canada
Jacques Bradwejn, Canada
Serge Brand, Switzerland
Karin Bruun-Plesner, Denmark
Lucia Caffino, Italy
Guodong Cao, USA
Yu Cao, China
Gregory D. Cascino, USA
Daniele Cavaleri, Italy
Hung-Yu Chan, Taiwan, Republic of China
Gideon Charach, Israel
Mu-Hong Chen, Taiwan, Republic of China
Wai Chen, Australia
Sofiène Chenini, France

Jacqueline M. Cohen, Norway
Erika Comasco, Sweden
John Corboy, USA
Ana Luisa Corona-Nakamura, Mexico
Sara Costi, USA
James R. Couch Jr, USA
Simon Couly, USA
Phil Cowen, UK
Suzanne Craft, USA
Benjamin Cretin, France
Wiesław J. Cubała, Poland
Aditi Das, USA
Anirban Das, Canada
John M. Davis, USA
Jose de Leon, USA
Filip De Vos, The Netherlands
Domenico Deberardis, Italy
John DeLuca, USA
Hans-Christoph Diener, Germany
Thomas C. Dowling, USA
Layne Dylla, USA
Tory A. Eisenlohr-Moul, USA
Joshua Eloge, USA
Simon Erridge, UK
Sebastian Euler, Switzerland
Rami Fakih, USA
Ingo Fietze, Germany
Urs Fisch, Switzerland
Michele Fornaro, USA
Anthony W. Fox, UK
Mark S. Freedman, Canada
David Gaist, Denmark
Vinay Goyal, India
David J. Greenblatt, USA
Kyle T. Greenway, Canada
Staci Gruber, USA
Kenji Hashimoto, Japan
Teruo Hayashi, Japan
Dorothee Heemskerk, The Netherlands
Anna Heidbreder, Austria
Madeleine Hinwood, Australia
Makoto Honda, Japan
Marion Houot, France
Robert H. Howland, USA
Bonaventure Y. Ip, China
Gabriel Jacobs, The Netherlands
Kurt Jellinger, Austria
Hong Jiang, China
Chong Jin, USA
Cecilie Johannessen Landmark, Norway
Mats Johnson, Sweden
Wolfgang H. Jost, Germany
Ulf Kallweit, Germany
Gary Kaplan, USA
Michael Kellner, Germany
Irina Kontsevaya, Germany
Christoph Kraus, USA
Edeltraut Kröger, Canada
Christine Kuehner, Germany
Yasutomo Kumakura, Japan
Dieter D. Kunz, Germany
Christian Lampl, Austria
Anne-Marie Landtblom, Sweden
Dawn Langdon, UK
Cynthia Lemere, USA
Mary A. Levasseur, Canada
Yuebing Li, USA
Matthias Liechti, Switzerland
Jean-Pierre Lindenmayer, USA
Anton J.M. Loonen, The Netherlands
Wolfgang Löscher, Germany
Phillip A. Low, USA
Angela Lupattelli, Norway
Melinda Magyari, Denmark
Paolo Martelletti, Italy
Kenichi Masui, Japan
Jeffrey A. Mattes, USA
Massimo C. Mauri, Italy
Geert Mayer, Germany
Robert A. McCutcheon, UK
Daniela O. Melo, Brazil
Grover P. Miller, USA
David Misdrahi, France
Nicholas A. Morris, USA
Suresh Muthukumaraswamy, New Zealand
Ahmed Nadeem, Saudi Arabia
Takahiko Nagamine, Japan
Manuel Narvaez Pelaez, Spain
David N. Neubauer, USA
Sarah Nevitt, UK
Jan Novy, Switzerland
Joel Oger, Canada
Renata Paolilo, Brazil
Athina Papadopoulou, Switzerland
Joel Paris, Canada
Botond Penke, Hungary
Keith R. Pennypacker, USA
Antoine Petitcollin, France
Alexandra Philipsen, Germany
Anne-Katrin Pröbstel, Switzerland
Nicolas Ramoz, France
Riju Ray, USA
D. Samba Reddy, USA
Maria A. Rocca, Italy
Alessandro Rodolico, Italy
Leonardo Roever, Brazil

Russell Rosenberg, USA
Andrea O. Rossetti, Switzerland
Marc-André Roy, Canada
Ley Sander, UK
Takehito Sato, Japan
Nina R. Schooler, USA
Peter F.J. Schulte, The Netherlands
Kwon Hui Seo, Republic of Korea
Gianluca Serafini, Italy
Kunal Shah, USA
Alessio Signori, Italy
Alok Singh, India
Gary W. Small, USA
Cesar A. Soutullo, USA
Richard J. Stark, Australia
Bernhard J. Steinhoff, Germany
Melissa D. Stockbridge, USA
Adam Strzelczyk, Germany
Cliff H. Summers, USA
Yuji Suzuki, Japan
Konrad Talbot, USA
Masakazu Terauchi, Japan
Praachi Tiwari, USA
Manuel Toledo, Spain
Alp Ucok, Turkey
Kimiaki Utsugisawa, Japan
Gustavo Vazquez, Canada
Javier Vázquez-Bourgon, Spain
Antonio Vita, Italy
Bruce Vrooman, USA
Liang-Jen Wang, Taiwan, Republic of China
Yujie Wang, China
Margaret C. Wardle, USA
Margaret D. Weiss, USA
Nicolas Weiss, France
Anna Wesołowska, Poland
Laurent M. Willems, Germany
Sue Wilson, UK
Yaroslav Winter, Germany
Yohannes W. Woldeamanuel, USA
Haimiao Yang, China
Min Yuan, China
Gaetano Zaccara, Italy
Martin Zack, Canada
Ashkan Zandi, Islamic Republic of Iran
Helene Zephir, France

Through the hard work of our authors and reviewers, we continue to see great gains in article usage. The most popular 2023 articles to date, in terms of downloads from SpringerLink, were:

- Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
- Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
- Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
- A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharm acokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults with Schizophrenia or Bipolar I Disorder
- Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease
- Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders
- Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation
- Pharmacological Management of Borderline Personality Disorder and Common Comorbidities
- Daridorexant in Insomnia Disorder: A Profile of Its Use
- Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Indiv iduals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials

Social media sharing and other online mentions of information are additional metrics with which to measure the reach of articles. This year the following articles published in *CNS Drugs* in the past 12 months have scored well on the Altmetric system:

- Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
- Network Meta-analysis of Different Treatments for Vestibular Migraine
- Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Indiv iduals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials
- Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review
- Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials

I hope that you have found the articles published throughout 2023 to be both interesting and informative. The Section Editors and I have appreciated the high quality of content contributed to the journal and we look forward to keeping you up to date with topical issues in the drug treatment of neurologic and psychiatric disorders in 2024.
With best wishes from the Editor of *CNS Drugs*.
Sue Pochon